Affimed N.V. logo
Affimed N.V. AFMD
report update icon

Quarterly report 2024-Q2
added 05-23-2026

Affimed N.V. Financial Ratios 2023-2011 | AFMD

Brief overview of Affimed N.V.'s financial ratios

The review covers five available annual periods spanning 2017 to 2021.

The current valuation set is P/S 13.06x (median 13.06x), P/B 2.34x (median 3.92x). On average, this basket is 20.1% below its own five-year medians. The market values the business at a discount to recent history.

The latest available business-quality ratios are ROE -183.3%, ROA -109%, ROCE -149.7%. Returns below zero mean resources are not producing positive profit. Recovery in operating results is the main reference point.

Current PEG of 3.06x points to a premium over forecast earnings momentum.

Conclusion

Affimed N.V.'s valuation is lower, but weak quality metrics call for caution. Recovery in earnings and capital returns is the key catalyst.

Annual Financial Ratios Affimed N.V.

2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

P/E

- - -9.2 -11.4 -4.7 -10.9 -3.1 -2.1 -4.5 -446.1 - - -

P/S

- - 13.1 16.7 7.1 8.9 46.2 10.5 12.0 34.3 - - -

EPS

-7.1 -6.0 -4.8 -0.5 -0.5 -0.3 -0.7 -1.0 -0.7 - - - -

EV (Enterprise Value)

-38.5 M -190 M 329 M 430 M 130 M 194 M 64.7 M 41.1 M 26.2 M 147 M 106 M 80.3 M -

EBITDA per Share

- - -0.54 -0.42 -0.5 -0.32 -0.62 -0.96 -0.75 -0.323 - - -

EV/EBITDA

0.4 2.2 -5.1 -12.4 -4.0 -9.9 -2.4 -1.3 -1.2 -13.0 - - -

PEG

- - 3.06 3.68 -0.18 -0.17 -0.06 0.03 0.0 -4.5 - - -

P/B

- - 2.3 6.6 3.9 5.3 2.9 1.7 1.4 3.6 - - -

P/CF

- - -6.1 -24.4 -5.2 4.3 -3.6 -2.1 -4.9 -12.6 - - -

ROE %

-183.26 -56.24 -42.31 -57.46 -83.70 -48.54 -77.69 -83.14 -30.08 -0.82 - - -

ROA %

-109.04 -42.89 -25.55 -23.54 -28.80 -16.77 -70.03 -66.10 -25.51 -0.62 - - -

ROCE %

-149.70 -53.13 -39.87 -31.94 -41.95 -24.63 -63.41 -75.63 -30.33 -22.91 - - -

Current Ratio

- - - 1.7 1.5 1.5 3.7 4.9 6.6 6.6 - - -

DSO

- - - 31.4 25.3 22.0 200.1 130.4 44.2 97.2 - - -

DIO

- - - - 69.8 83.2 88.5 69.9 92.3 86.9 - - -

DPO

- - - - 2518.4 3017.7 1534.9 1890.0 1798.3 1651.2 - - -

Operating Cycle

- - - 31.4 95.1 105.2 288.6 200.3 136.4 184.1 - - -

Cash Conversion Cycle

- - - 31.4 -2423.3 -2912.4 -1246.3 -1689.7 -1661.9 -1467.1 - - -

All numbers in EUR currency

Quarterly Financial Ratios Affimed N.V.

2024-Q2 2023-Q4 2023-Q3 2023-Q2 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

EPS

-1.01 -7.09 - -0.2 - - -0.13 - -4.81 - -0.16 - -0.5 - -0.16 - -0.5 - -0.17 - -0.32 - -0.13 - -0.69 - - - -0.97 - - - -0.71 - - - - - - - - - - - - - - - - - - -

EBITDA per Share

-1.02 - - -0.2 - - -0.15 - -0.54 - -0.14 - -0.42 - -0.14 - -0.5 - -0.16 - -0.32 - -0.15 - -0.62 - - - -0.96 - - - -0.75 - - - - - - - - - - - - - - - - - - -

ROE %

-276.85 -265.35 -82.09 -94.52 -64.81 -64.81 -122.26 -112.20 -142.41 -100.10 -183.80 -171.38 -202.86 -145.40 -193.93 -163.72 -180.70 -97.00 -174.69 -143.21 -226.34 -177.81 -207.89 -190.91 -77.69 - - - -83.14 - - - -30.08 - - - - - - - - - - - - - - - - - - -

ROA %

-167.36 -163.85 -54.81 -62.37 -40.55 -40.55 -64.09 -56.65 -68.75 -43.20 -72.00 -64.44 -74.88 -51.34 -68.10 -56.00 -126.03 -97.23 -163.33 -152.89 -16.77 - - - -70.03 - - - -66.10 - - - - - - - - - - - - - - - - - - - - - - -

ROCE %

-229.73 -227.00 -77.30 -86.81 -59.75 -59.75 -91.69 -81.32 -97.76 -57.88 -99.83 -90.32 -103.67 -71.73 -96.36 -79.92 -99.24 -57.29 -120.70 -107.35 -182.99 -158.36 -190.09 -170.77 -63.41 - - - -75.63 - - - -31.73 - - - - - - - - - - - - - - - - - - -

All numbers in EUR currency

Multiples are an important financial analysis tool for the company Affimed N.V., allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.

Advantages of Using Financial Ratios
  • Simplified Data Analysis
    Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition.
  • Comparability Between Companies
    Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations.
  • Identification of Trends and Issues
    Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks.
  • Decision Support
    Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions.
  • Accelerated Assessment of Investment Attractiveness
    Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.

Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.

Financial Ratios of other stocks in the Biotechnology industry

Issuer Price % 24h Market Cap Country
Фармсинтез Фармсинтез
LIFE
- - - russiaRussia
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
- -1.52 % $ 24.7 M usaUSA
Завод ДИОД Завод ДИОД
DIOD
- - - russiaRussia
Aptose Biosciences Aptose Biosciences
APTO
- -45.71 % $ 1.2 M canadaCanada
Cleveland BioLabs, Inc. Cleveland BioLabs, Inc.
CBLI
- -7.31 % $ 49 M usaUSA
Five Prime Therapeutics, Inc. Five Prime Therapeutics, Inc.
FPRX
- - $ 1.77 B usaUSA
Aravive Aravive
ARAV
- -13.39 % $ 1.45 M usaUSA
Arena Pharmaceuticals Arena Pharmaceuticals
ARNA
- -6.81 % $ 3.04 B usaUSA
Biofrontera AG Biofrontera AG
BFRA
- -8.24 % $ 105 M germanyGermany
Catabasis Pharmaceuticals, Inc. Catabasis Pharmaceuticals, Inc.
CATB
- -6.97 % $ 657 M usaUSA
China Biologic Products Holdings, Inc. China Biologic Products Holdings, Inc.
CBPO
- 1.68 % $ 4.65 B chinaChina
Flexion Therapeutics, Inc. Flexion Therapeutics, Inc.
FLXN
- - $ 459 M usaUSA
Heat Biologics, Inc. Heat Biologics, Inc.
HTBX
- -5.76 % $ 99.8 M usaUSA
Kindred Biosciences, Inc. Kindred Biosciences, Inc.
KIN
- 0.11 % $ 419 M usaUSA
Shineco, Inc. Shineco, Inc.
TYHT
- -3.90 % $ 97.2 M chinaChina
Millendo Therapeutics, Inc. Millendo Therapeutics, Inc.
MLND
- -5.36 % $ 20.2 M usaUSA
Intec Pharma Ltd Intec Pharma Ltd
NTEC
- -12.45 % $ 17.7 M israelIsrael
Progenity, Inc. Progenity, Inc.
PROG
- -3.47 % $ 164 M usaUSA
CTI BioPharma Corp. CTI BioPharma Corp.
CTIC
- - $ 1.2 B usaUSA
Strongbridge Biopharma plc Strongbridge Biopharma plc
SBBP
- 1.52 % $ 136 M usaUSA
Decibel Therapeutics Decibel Therapeutics
DBTX
- - $ 123 M usaUSA
Seneca Biopharma, Inc. Seneca Biopharma, Inc.
SNCA
- -1.19 % $ 28.7 M usaUSA
IVERIC bio IVERIC bio
ISEE
- - $ 5.51 B usaUSA
Myovant Sciences Ltd. Myovant Sciences Ltd.
MYOV
- -0.04 % $ 2.62 B usaUSA
Trean Insurance Group Trean Insurance Group
TIG
- - $ 316 M usaUSA
Virpax Pharmaceuticals Virpax Pharmaceuticals
VRPX
- -45.12 % $ 2.85 M usaUSA
Metacrine Metacrine
MTCR
- - $ 24.2 M usaUSA
Celsion Corporation Celsion Corporation
CLSN
- -6.63 % $ 13.9 M usaUSA
Генетико Генетико
GECO
- - - russiaRussia
I-Mab I-Mab
IMAB
- - $ 866 M chinaChina
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
- - $ 40.3 B usaUSA
AnaptysBio AnaptysBio
ANAB
$ 56.8 0.94 % $ 1.63 B usaUSA
Genfit SA Genfit SA
GNFT
- 2.54 % $ 160 B franceFrance
Biophytis SA Biophytis SA
BPTS
- -13.47 % $ 169 M franceFrance
CureVac N.V. CureVac N.V.
CVAC
- - $ 867 M germanyGermany
BiondVax Pharmaceuticals Ltd. BiondVax Pharmaceuticals Ltd.
BVXV
- 0.74 % $ 768 M israelIsrael
Abcam plc Abcam plc
ABCM
- - $ 4.9 B britainBritain
Midatech Pharma plc Midatech Pharma plc
MTP
- -18.52 % $ 27.3 M britainBritain
MorphoSys AG MorphoSys AG
MOR
- 2.43 % $ 254 M germanyGermany
ОЗОН Фармацевтика ОЗОН Фармацевтика
OZPH
- - - russiaRussia
AnPac Bio-Medical Science Co., Ltd. AnPac Bio-Medical Science Co., Ltd.
ANPC
- -1.58 % $ 28.1 M chinaChina
Celyad Oncology SA Celyad Oncology SA
CYAD
- - $ 12.5 M belgiumBelgium
Gracell Biotechnologies Gracell Biotechnologies
GRCL
- - $ 3.37 B chinaChina
Galapagos NV Galapagos NV
GLPG
- - $ 1.83 B belgiumBelgium
Teligent, Inc. Teligent, Inc.
TLGT
- -13.85 % $ 16.1 M usaUSA
Viela Bio, Inc. Viela Bio, Inc.
VIE
- - $ 2.91 B usaUSA
Applied Molecular Transport Applied Molecular Transport
AMTI
- - $ 10.1 M usaUSA
Aphria Inc. Aphria Inc.
APHA
- -0.45 % $ 4.87 B canadaCanada
Aerpio Pharmaceuticals, Inc. Aerpio Pharmaceuticals, Inc.
ARPO
- -0.90 % $ 104 M usaUSA